Virtus Fund Advisers, LLC Halozyme Therapeutics, Inc. Transaction History
Virtus Fund Advisers, LLC
- $25 Million
- Q2 2024
A detailed history of Virtus Fund Advisers, LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Virtus Fund Advisers, LLC holds 757 shares of HALO stock, worth $45,155. This represents 0.16% of its overall portfolio holdings.
Number of Shares
757
Previous 750
0.93%
Holding current value
$45,155
Previous $30,000
30.0%
% of portfolio
0.16%
Previous 0.11%
Shares
4 transactions
Others Institutions Holding HALO
# of Institutions
521Shares Held
123MCall Options Held
208KPut Options Held
77.1K-
Black Rock Inc. New York, NY17.6MShares$1.05 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.9MShares$768 Million0.01% of portfolio
-
State Street Corp Boston, MA5.81MShares$347 Million0.01% of portfolio
-
Snyder Capital Management L P San Francisco, CA4.04MShares$241 Million4.92% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI3.72MShares$222 Million0.31% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $8.31B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...